Samsung Electronics and the Diabetes Research Center at Massachusetts General Hospital announced a joint clinical study on May 28, 2026 to test whether a smartwatch can help patients starting GLP-1 receptor agonist therapy hold onto muscle while they lose weight. The study puts Galaxy Watch8 devices on the wrists of 100 adults beginning treatment with the class of drugs that includes semaglutide and tirzepatide, betting that continuous activity and body composition data can catch a problem that often goes unmeasured until it is already advanced.
The Problem GLP-1 Drugs Created
GLP-1 medications, sold under brand names such as Ozempic, Wegovy and Zepbound, have become the default weight-loss treatment for millions of American adults, with survey data cited by researchers indicating that nearly one in five U.S. adults report having taken one. But the rapid, large-scale weight loss the drugs produce comes with a documented downside: clinical trials in the drugs’ own development programs, including the STEP research program for semaglutide, have repeatedly found that a substantial share of total weight lost, sometimes cited as a third or more, comes from lean muscle mass rather than fat. Losing muscle at that pace can weaken older adults in particular, raising fall risk and undermining the very metabolic health the drugs are meant to improve. Endocrinologists have flagged the issue for several years, but until now there has been no widely used, low-cost way to track muscle loss outside a research lab, leaving most patients and their primary care doctors largely blind to what is happening to body composition between office visits.
Watching Body Composition in Real Time
The Samsung-MGH study uses the Galaxy Watch8’s bioelectrical impedance analysis sensor, the same underlying technology used in some smart scales, to estimate body composition continuously rather than through periodic clinic visits. One group of participants will receive personalized exercise guidance generated from that continuous data, while a control group receives the standard counseling typically given to patients starting GLP-1 therapy. Researchers will then compare outcomes in both groups using DXA scans, the dual-energy X-ray absorptiometry technology considered the clinical gold standard for measuring body composition, to determine whether wearable-guided coaching actually preserves more muscle than standard care.
Why a Hospital Partnered With a Phone Maker
The collaboration reflects a broader trend of hospitals turning to consumer electronics companies for continuous, low-cost monitoring that would be impractical to replicate with clinical-grade equipment alone. Rather than asking patients to visit a lab every few weeks, MGH researchers can pull daily activity and body composition signals passively from a device patients already wear. It is a model increasingly common in what is sometimes called hospital-at-home research, where wearable sensors extend a clinical team’s visibility into a patient’s life well beyond the exam room. MGH’s Diabetes Research Center has run similar wearable-based studies in the past for other metabolic conditions, and researchers there have said the appeal of the Galaxy Watch8 partnership is that it does not require recruiting participants to buy new hardware, since the device is already commercially available and widely owned.
Cautious Optimism, With Caveats
Samsung has cast the study as an example of consumer hardware graduating into legitimate clinical research, and MGH’s involvement lends the effort institutional credibility that a corporate wellness claim alone would lack. But the study’s own design contains an implicit acknowledgment of the technology’s limits: researchers chose to validate the watch’s readings against DXA scans precisely because wrist-based bioelectrical impedance is understood to be a rougher instrument than dedicated body-composition equipment. With only 100 participants, the trial is also too small on its own to produce definitive clinical guidance, and its authors have described it as an investigation into feasibility rather than a conclusive efficacy trial.
What It Means for GLP-1 Patients
If the study finds that watch-guided exercise coaching meaningfully preserves muscle compared with standard care, it could give physicians a low-cost tool to recommend alongside GLP-1 prescriptions, potentially without requiring patients to purchase separate clinical monitoring. It would also give Samsung a genuine clinical data point to cite as it competes with Apple and Google in health-focused wearables. For the millions of patients already on these drugs without any structured muscle-preservation plan, the research could eventually translate into simple, personalized activity targets delivered straight to a watch face, rather than generic advice to just add some strength training and hope for the best.
